Eptifibatide is noninferior to abciximab: implications for clinical practice

Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

OBJECTIVES The aim of this study was to test the noninferiority of eptifibatide relative to abciximab in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). BACKGROUND Glycoprotein IIb/IIIa inhibitors are recommended by international guidelines in patients with acute coronary syndromes undergoing PCI. Abciximab is rec...

Quantitative Dengue Test: Is it Practical for Clinical Practice?

Comparative efficacy of eptifibatide and abciximab in primary angioplasty study

Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.

OBJECTIVES The goal of this study was to evaluate platelet function and to preliminarily assess the clinical safety of sequential treatment with tirofiban or eptifibatide followed by abciximab in patients undergoing percutaneous coronary intervention (PCI). BACKGROUND An increasing number of acute coronary syndrome (ACS) patients are treated early with tirofiban or eptifibatide. Some later re...

quantitative dengue test: is it practical for clinical practice?